Nymox Pharma (NYMX) Halted on LUDP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Nymox Pharma (NYMX) Mentioned Cautiously by Feuerstein
October 11, 2016 10:25 AM EDTNymox Pharma (NASDAQ: NYMX) was mentioned cautiously by theStreet's Adam Feuerstein on twitter. Earlier shares spiked after it announced successful new study results from the long-term repeated injection group from the U.S. Phase 3 trials for... More
Nymox Pharma (NYMX) Halted on Second LUDP
October 11, 2016 10:07 AM EDTNymox Pharma (NASDAQ: NYMX) Halted on Second LUDP
... MoreNymox Pharma (NYMX) Announces Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results
October 11, 2016 10:02 AM EDTNymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce successful new study results from the long-term repeated injection group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate (BPH) and for localized... More
